How to Choose a Local Agent for Medical Device Registration in South Korea?

Direct answer: When selecting a local agent for medical device registration in South Korea, a manufacturer should first confirm the target country, the product's risk classification, the applicable regulatory pathway and the existing documentation base, and only then evaluate the technical file, quality management system evidence, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. Completing a documentation gap assessment before formal submission is the most effective way to avoid extended project timelines caused by unclear classification, missing files or undefined authorisation arrangements.

Published: 2026-07-15 16:58 | Updated: 2026-07-15 16:58

Key Takeaways

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market usually affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by a list of documents to be submitted, corrections or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control.

AIMEILI recommends placing this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation across different markets, rather than rebuilding documentation on a country-by-country basis.

This content is compiled from AIMEILI's regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the product's own documentation base.

Applicable Scenarios and Core Questions

Companies searching for guidance on how to choose a local agent for medical device registration in South Korea are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support an application in the target market, whether a local agent or authorised representative is required, why timelines become extended, and which issues could affect the launch plan. Behind this question there are typically several linked topics: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East or Latin America at the same time, answering the process question for a single country is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the product's intended use, mechanism of action, use scenario, mode of body contact, duration of use, whether it is sterile, whether it is active (powered), and whether it has software or IVD characteristics, and then determine the risk class and submission pathway. Once the pathway judgement is wrong, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains the documentation for certificate renewal. If these issues are only addressed vaguely in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many documents the company has uploaded.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated NMPA documentation without reorganising the evidence according to the target market pathway.
• Including too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent purely on the basis of a sales partnership, without defining regulatory responsibilities, certificate control and post-market maintenance duties.
• Inconsistency between labelling, instructions for use, promotional material and registration documentation, leading to correction requests or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that documentation is rebuilt for every country and both cost and timelines are inflated.

Manufacturer Preparation Checklist

Before starting the project, companies should confirm their documentation base against an internal checklist so that key evidence gaps are not discovered only after submission.

• Compile the target product list, the model and specification matrix and the intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the local agent's or authorised representative's duties, fees, certificate control and exit mechanism.
• Establish a gap assessment table for the target country, identifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to view target market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter several countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than filling documentation gaps on an ad hoc, country-by-country basis, and it also makes later changes and certificate renewal easier to manage.

From a project management perspective, three items should be controlled as early as possible: first, product classification and pathway determination; second, evidence chain consistency across the documentation; third, the regulatory responsibility boundaries of the local partner. If these three items are unclear, a project may still face repeated corrections, agent communication problems and post-market maintenance issues even when the documentation appears substantial.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for registration in the target market?

Domestic documentation can serve as a basis, but it normally cannot be submitted as it stands. Companies must adjust the documentation structure, language, labelling, authorisation documents and evidence chain to meet local regulatory requirements.

When is the best time to start the gap assessment?

The gap assessment should start immediately after the target market and product list have been confirmed. The earlier it is completed, the earlier additional testing, translation, label adjustments and agent selection can be arranged.

Why does the choice of local agent affect registration quality?

The local agent typically participates in regulatory communication, change filings, certificate renewal and post-market event handling. If responsibilities are not clearly defined, certificate control and subsequent market stability can be affected.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project register that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible early and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix specifying which documents can serve as core evidence and which must be reissued or supplemented to meet national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept at consistent versions.

• Confirm the target market and the product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent's role and certificate control.
• Track translation, notarisation, testing and correction status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being filed, or if the manufacturing address, model specifications or instructions for use version do not match the test reports, additional explanations may be requested even where a large volume of documentation has been prepared.

Before submission, companies should create an evidence consistency check table that maps product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This step may appear basic, but it significantly reduces the probability of correction requests, particularly for projects filing simultaneously in several GHWP member states or across multiple product families.

Localisation and Agent Responsibilities

A target market registration project usually involves arrangements with a local agent, authorised representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documentation, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into an application structure acceptable in the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean the compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and when a manufacturing site change, model extension, instructions for use update or agent replacement occurs, the certificate can become disconnected from actual market sales.

AIMEILI recommends managing this topic within an annual international registration plan: define target market priorities first, then build a reusable documentation package and a country gap list, and finally schedule submission, correction, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country; more importantly, it allows a company to develop a replicable compliance capability for going global, reducing the cost of rebuilding documentation from scratch each time it enters a new market.

Continue Reading

Previous: How Is an ISO 13485 Certificate Used for Medical Device Registration in South Korea?

Next: How Are Authorised Representative Responsibilities Divided for Medical Device Registration in South Korea?

Recommended reading:

• How to Choose a Local Agent for Medical Device Registration in Brazil?
• How Are Authorised Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Do Medical Device Registration Timelines in Brazil Get Extended?
• What Are the Common Reasons for Documentation Corrections in Brazilian Medical Device Registration?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Filed for Medical Devices in Brazil?

Back to FAQ Centre | News | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.